BioArctic AB products

BioArctic has developed a technology platform that has proven to be successful when the company’s first drug candidate was developed, the antibody BAN2401 for Alzheimer´s disease. Our mission is to improve quality of life for patients suffering from Central Nervous System (CNS) disorders. Patients with neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease will be treated with antibodies targeting the misfolded proteins in these disorders. Our technology is now applied to other CNS disorders like Parkinson’s disease, and novel antibodies are being developed.

In Alzheimer’s disease soluble, toxic amyloid beta aggregates are believed to contribute to the neurodegenerative process. Lecanemab, a anti amyloid-beta protofibril antibody, selectively binds to these forms of amyloid beta and eliminates them. The antibody’s unique profile is highly selective for amyloid beta oligomers/protofibrils in the brain. BioArctic’s belief is that lecanemab’s unique binding profile is important and differentiates it from other amyloid beta antibodies.

AD1801 is an innovative project to develop disease modifying treatment of Alzheimer’s disease, targeting Apolipoprotein E (ApoE), a different molecule than those targeted in the projects BAN2401 and BAN2401 back-up.

At BioArctic, research is in progress to develop new antibodies for the treatment of Alzheimer’s disease aimed at slowing down or stopping disease progression by addressing novel targets.

The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease progression.

The antibody PD1601 is targeting alpha-synuclein for treatment of Parkinson’s disease. The aim is to develop a disease modifying treatment that stops or slows down disease progression. The project is conducted in collaboration with AbbVie.

The antibody PD1602 is targeting alpha-synuclein for treatment of Parkinson’s disease. The aim is to develop a disease modifying treatment that stops or slows down disease progression. The project is conducted in collaboration with AbbVie.

Research to develop new antibodies for treating neurodegenerative disorders is under way at BioArctic. the ND3014 project aims to develop selective antibody treatments targeting TDP-43, a protein that is believed to play a crucial role in the development of the rare neurodegenerative disease ALS (amyotrophic lateral sclerosis).